{"id":"05697","slug":"rat-monoclonal-antibody-to--05697","source":{"id":"05697","dataset":"techtransfer","title":"Rat Monoclonal Antibody to SARS CoV2 RdRp","description_":"<p>Researchers at the University of Pittsburgh have developed a novel rat monoclonal antibody targeting a specific peptide epitope on the SARS CoV2 RNA-dependent RNA polymerase (RdRp) protein. RdRp is essential for viral replication and is the target for antiviral drugs such as remdesivir. This antibody is highly specific and compatible with various laboratory techniques, including immunoblotting, immunofluorescence assays (IFA), immunohistochemistry (IHC), and immunoprecipitation. This breakthrough offers a valuable tool for basic research on SARS CoV2, potential drug discovery, and as a diagnostic reagent.</p><p><h2>Description</h2>The technology involves the creation of a rat monoclonal antibody that specifically binds to a peptide epitope on the SARS CoV2 RdRp protein. This antibody is the first of its kind and provides a new avenue for researchers to study the replication machinery of the virus. The antibodies can be used in a variety of applications, from identifying and studying protein interactions to serving as a diagnostic tool for detecting the presence of the RdRp protein in infected cells.</p><p><h2>Applications</h2>- Basic Research\r<br>- Drug Discovery\r<br>- Diagnostic Reagent</p><p><h2>Advantages</h2>This rat monoclonal antibody provides a unique and specific tool for researchers working on SARS CoV2. It supports multiple research techniques, making it a versatile addition to the laboratory toolkit. As the first monoclonal antibody against SARS CoV2 RdRp, it fills a critical gap in research and diagnostic capabilities, aiding in the fight against COVID-19.</p><p><h2>Invention Readiness</h2>The antibody has been validated in vitro, with ongoing collaborations to further its development. The invention is ready for licensing and commercialization opportunities, providing a valuable resource for both research and clinical applications.</p><p><h2>IP Status</h2>Research Tool</p><p></p>","tags":[],"file_number":"05697","collections":[],"meta_description":"Novel rat monoclonal antibody targets SARS-CoV-2 RdRp, enabling multi-technique research, diagnostics, and drug discovery.\n\n","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":3.0,\"readiness\":3.0,\"scalability\":2.0,\"timeliness\":2.0},\"weighted_score\":2.95,\"risks\":[\"RdRp-targeting antibody is novel but limited utility to RdRp studies; may have niche applicability\",\"Therapeutic potential uncertain; IP status is non-clinical (research tool) limiting translational value\",\"Technology Readiness Level 2 suggests early-stage validation; path to product uncertain\"],\"one_sentence_take\":\"High novelty as the first RdRp-targeting antibody with broad research utility, but readiness and scalability are modest and time-sensitive translational potential is uncertain.\"}","lead_inventor_name":"Patrick Moore","lead_inventor_dept":"Med-Pathology","technology_type":"Therapeutic Modality","technology_subtype":"Antibody - mAb","therapeutic_areas":["Infectious Disease"],"therapeutic_indications":["Covid-19"],"custom_tags":[],"all_tech_innovators":["Yuan Chang","Patrick S. Moore"],"date_submitted":"2021-05-19","technology_readiness_level":"2. Initial proof of concept, in-vitro"},"highlight":{},"matched_queries":null,"score":0.0}